DataMeds cuts costs and refocuses on ChemoFx after Helomics acquisition

DataMeds AI said it is cutting corporate management jobs to concentrate spending on ChemoFx, its precision oncology lab test for gynecologic cancers. The company also said ChemoFx was added to a Humana Medicaid coverage policy, a potential boost to reimbursement and commercialization.

Why it matters: - DataMeds is shifting resources toward a product it believes can drive near-term revenue: the ChemoFx assay for guiding chemotherapy choices in gynecologic cancers. - The Humana Medicaid coverage policy could improve access and reimbursement for the test, which matters for adoption by oncologists and payers. - The move follows DataMeds’ Sept. 11 acquisition of Helomics Corporation, bringing the CLIA lab and Predictive Oncology division in-house.

What happened: - DataMeds AI said it has implemented cost controls, including reductions in corporate management positions. - The company said the goal is to focus workforce spending on commercializing ChemoFx as a diagnostic lab test. - ChemoFx is being positioned initially for gynecologic cancers only. - DataMeds said ChemoFx was included for the first time in a Humana Medicaid coverage policy for gynecologic cancers. - The company said it acquired Helomics Corporation on Sept. 11, 2026, including Helomics’ Predictive Oncology Cancer Biomarker Super Intelligence division.

The details: - Interim Co-CEO Gerald E. Commissiong said ChemoFx has been commercially available in the U.S. since 1997. - ChemoFx has two CPT codes, 81535 and 81536. - DataMeds said the test has been optimized through continued automation for high-volume use. - Prior ownership generated peak historical annual revenues above $25 million, according to the company. - DataMeds is preparing to relaunch a marketing campaign for ChemoFx. - The company cited a 2015 peer-reviewed PLOS publication that reviewed evidence supporting the clinical utility and cost-effectiveness of ChemoFx in epithelial ovarian cancer. - DataMeds said it is preparing additional clinical utility analyses for peer review in other solid tumors. - Predictive Oncology controls more than 70,000 de-identified tumor samples linked to de-identified clinical data across more than 130 tumor types. - The repository includes about 20,000 ovarian cancer samples. - DataMeds plans to seek research collaborations, including with frontier lab developers, using de-identified data from the tumor samples. - The company said those collaborations could support discovery of new therapeutic targets using the sample repository and proprietary organoid technology. - DataMeds has started discussions with hospital systems, HMOs, group purchasing organizations and specialty cancer treatment centers to add ChemoFx to cancer testing programs where appropriate. - The company plans to develop an oncology support module inside the Health Lives Here app, which is available on Android and iOS. - DataMeds said the app will help consolidate electronic health records data and integrate wearable data into a health dashboard. - Corexa Health’s pharmacy and distribution divisions are licensed to dispense and distribute chemotherapeutic drugs. - Patients and providers using ChemoFx can choose their own pharmacy. - Tollo Health manufactures medical foods and dietary supplements. - Tollo plans targeted nutritional support programs for cancer patients with leading oncologists. - Helomics operates a CLIA-certified laboratory in Pittsburgh focused on precision oncology. - ChemoFx tests a patient’s live tumor cells against a panel of chemotherapy agents to help inform treatment decisions in gynecologic cancers. - ChemoFx is a laboratory-developed test and has not been cleared or approved by the U.S. Food and Drug Administration.

Between the lines: - DataMeds is trying to simplify its corporate structure while concentrating on a narrower set of products with clearer reimbursement and clinical use cases. - The company is pairing a legacy lab test with AI, data, and biobank assets to pitch a broader oncology platform, not just a single assay. - The reliance on de-identified tumor data and outside research partners signals an effort to turn the Helomics acquisition into both a commercial and research asset. - Historical revenue, prior reimbursement wins, and published studies may help the relaunch, but none guarantee future uptake.

What's next: - DataMeds expects to relaunch ChemoFx marketing. - The company plans to prepare more clinical utility data for publication. - DataMeds will continue talks with health systems and cancer centers about adding ChemoFx to testing programs. - The company also plans to build out the Health Lives Here oncology module and pursue research collaborations around its tumor sample repository. - DataMeds said future reimbursement, adoption, and collaboration outcomes remain uncertain.

The bottom line: - DataMeds is betting that cost cuts, a Medicaid coverage win, and Helomics’ lab and data assets can revive ChemoFx as a more commercially focused oncology business.